Abstract:Abstract Brain metastases (BrMs) represent an unmet challenge for the therapy of most aggressive cancers owing to the extremely poor survival and the limited efficacy of available therapies. Currently, NO curative therapy for breast cancer BrM (BCBrM) is available and we urgently need to develop new and effective therapies. Immune checkpoint therapies (ICT) have revolutionized cancer treatment, but are generally unsuccessful in treating BrMs, including BCBrM. A crucial reason for this is the unique brain immune microenvironment with low antigen exposure/presentation in BrMs and fewer antigen-specific T cells in the brain parenchyma. The priming and activation of antigen-specific T cells require professional antigen-presenting dendritic cells (DCs) for effective antigen presentation through multifaceted communication between DCs and T cells by direct intercellular contact and indirect distant communication via exosomes and other means. DC-derived exosomes (DCEXs) carry functional MHC-I/peptide complexes (pMHC-I) and costimulatory molecules, hence facilitating systemic T cell immune responses. DCEXs have been developed as immunotherapies which exhibit advantages over DC-based immunotherapies. However, DCEXs in ongoing clinical trials showed limited efficacy. We found that increased non-receptor protein tyrosine phosphatase SHP1, a DC-intrinsic inhibitory checkpoint, in monocyte-derived DCs (MoDCs) ex vivo led to DC exhaustion that limits DCEXs function resulting in poor systemic T cells stimulation in vivo. To improve DCEXs functions, we developed next-generation DCEXs by genetic knockout of SHP1 in DCs from which DCEXs (iSHP1-DCEXs) were isolated. Remarkably, the modified iSHP1-DCEXs exhibited significantly increased pMHC-I expression and more effectively improved T cell proliferation compared to control DCEXs, indicating a greater capacity of antigen presentation of engineered iSHP1-DCEXs. In the EO771-OVA mammary tumor cells-bearing mouse model, iSHP1-DCEXs treatment greatly increased tumor infiltration of OVA antigen-specific CD8+ T (OT-1) cells resulting in tumor inhibition and prolonged mouse survival, indicating that iSHP1-DCEXs elicited an effective and specific antitumor immunity in vivo. Moreover, combining iSHP1-DCEXs with anti-PD1 Ab yielded a strong syngenetic therapeutic response in mice bearing the anti-PD1-resistant EO771 tumors, as indicated by delayed tumor growth and prolonged survival. importantly, iSHP1-DCEXs also significantly increased tumor-infiltrating antigen-specific T cells and synergized with PD-1 Ab leading to tumors clearance in mice bearing the B16-GMCSF melanoma. To further test the iSHP1-DCEXs effect in BCBrM, we co-injected EO771-OVA and iSHP1-DCEXs into mice and found that iSHP1-DCEXs inhibited BrM. Together, the engineered iSHP1-DCEXs offer a promising option to generate a potent antigen-specific T cell immune response for BCBrM inhibition. Citation Format: Hao-Nien Chen, Xiangliang Yuan, Yimin Duan, Yi Xiao, Shao-Ping Yang, DIhua Yu. Engineering dendritic cell-derived exosomes forbrain metastases immunotherapy. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5077.

Alarmin-painted exosomes elicit persistent antitumor immunity in large established tumors in mice

Therapeutic Effect of MIP-1alpha-recruited Dendritic Cells on Preestablished Solid and Metastatic Tumors.

More efficient induction of antitumor T cell immunity by exosomes from CD40L gene-modified lung tumor cells.

Enhanced induction of dendritic cell maturation and HLA-A*0201-restricted CEA-specific CD8 + CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells

Increasing the Immune Activity of Exosomes: the Effect of Mirna-Depleted Exosome Proteins on Activating Dendritic Cell/cytokine-Induced Killer Cells Against Pancreatic Cancer.

PD-L1+ Exosomes from Bone Marrow-Derived Cells of Tumor-Bearing Mice Inhibit Antitumor Immunity

Universal immunotherapeutic strategy for hepatocellular carcinoma with exosome vaccines that engage adaptive and innate immune responses

TGF-β1-silenced leukemia cell-derived exosomes target dendritic cells to induce potent anti-leukemic immunity in a mouse model

Suppression of Established Hepatocarcinoma in Adjuvant Only Immunotherapy: Alum Triggers Anti-Tumor CD8+ T Cell Response.

Tumor Cell-associated Exosomes Robustly Elicit Anti-tumor Immune Responses through Modulating Dendritic Cell Vaccines in Lung Tumor

Co-delivery of Tumor-Derived Exosomes with Alpha-Galactosylceramide on Dendritic Cell-Based Immunotherapy for Glioblastoma

Allogeneic Dendritic Cells Induce Potent Antitumor Immunity by Activating KLRG1+CD8 T Cells

Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer

Tumor-repopulating cell-derived microparticles elicit cascade amplification of chemotherapy-induced antitumor immunity to boost anti-PD-1 therapy

Dual effect of DLBCL-derived EXOs in lymphoma to improve DC vaccine efficacy in vitro while favor tumorgenesis in vivo

Cell microparticles loaded with tumor antigen and resiquimod reprogram tumor-associated macrophages and promote stem-like CD8+ T cells to boost anti-PD-1 therapy

Abstract 2476: Electroporation-mediated novel albumin-fused Flt3L DNA delivery promotes cDC1-associated anticancer immunity

Remodeling Tumor-Associated Neutrophils to Enhance Dendritic Cell-Based HCC Neoantigen Nano-Vaccine Efficiency

Abstract 5077: Engineering dendritic cell-derived exosomes forbrain metastases immunotherapy

PD-L1 Antibodies-Armed Exosomal Vaccine for Enhanced Cancer Immunotherapy by Simultaneously in Situ Activating T Cells and Blocking PD-1/PD-L1 Axis

Proinflammatory allogeneic dendritic cells enhance the therapeutic efficacy of systemic anti-4-1BB treatment